Nifty
:
10804.35
Sensex
:
36340.69
-36.30 (-0.33%)
-223.19 (-0.61%)
Nifty
Sensex
:
:
10804.35
36340.69
-36.30 (-0.33%)
-223.19 (-0.61%)

Aurobindo Pharma Ltd.

Pharmaceuticals & Drugs

Rating :
63/99

BSE: 524804 | NSE: AUROPHARMA

NSE BSE
618.75
18-Sep-2019
  • Open
  • High
  • Low
  • Previous Close
  •  620.00
  •  622.50
  •  609.50
  •  616.70
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1452851
  •  8954.19
  •  838.00
  •  536.60

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 36,266.67
  • 14.25
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 41,276.25
  • 0.40%
  • 2.50

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.87%
  • 3.10%
  • 8.47%
  • FII
  • DII
  • Others
  • 0.06%
  • 13.21%
  • 23.29%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.53
  • 10.05
  • 9.48

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.99
  • 9.04
  • 2.85

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.46
  • 8.43
  • 0.94

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.10
  • 19.19
  • 17.07

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.07
  • 5.04
  • 3.72

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 13.16
  • 13.25
  • 11.73

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Net Sales
5,444.60
4,250.27
28.10%
5,292.20
4,049.09
30.70%
5,269.67
4,336.11
21.53%
4,751.40
4,435.89
7.11%
Expenses
4,298.20
3,539.21
21.45%
4,234.73
3,260.98
29.86%
4,183.29
3,310.53
26.36%
3,765.13
3,319.01
13.44%
EBITDA
1,146.40
711.06
61.22%
1,057.47
788.11
34.18%
1,086.38
1,025.58
5.93%
986.27
1,116.88
-11.69%
EBIDTM
21.06%
16.73%
19.98%
19.46%
20.62%
23.65%
20.76%
25.18%
Other Income
15.78
43.73
-63.91%
32.27
43.83
-26.37%
63.85
33.05
93.19%
26.26
10.27
155.70%
Interest
49.89
29.54
68.89%
50.08
24.72
102.59%
47.65
18.86
152.65%
35.39
17.27
104.92%
Depreciation
240.86
154.53
55.87%
186.62
156.63
19.15%
163.12
138.08
18.13%
163.68
132.08
23.92%
PBT
858.73
570.72
50.46%
816.86
650.59
25.56%
914.42
901.69
1.41%
786.62
977.80
-19.55%
Tax
227.76
115.54
97.13%
231.12
122.39
88.84%
204.78
306.94
-33.28%
175.42
197.96
-11.39%
PAT
630.97
455.18
38.62%
585.74
528.20
10.89%
709.64
594.75
19.32%
611.20
779.84
-21.62%
PATM
11.59%
10.71%
11.07%
13.04%
13.47%
13.72%
12.86%
17.58%
EPS
10.85
7.78
39.46%
9.99
9.02
10.75%
12.16
10.16
19.69%
10.44
13.33
-21.68%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
20,757.87
19,563.55
16,463.03
14,909.54
13,794.65
12,120.52
8,099.79
5,855.32
4,627.40
4,381.48
3,575.44
Net Sales Growth
21.59%
18.83%
10.42%
8.08%
13.81%
49.64%
38.33%
26.54%
5.61%
22.54%
 
Cost Of Goods Sold
9,103.94
7,886.32
6,162.23
5,911.00
5,612.30
5,099.89
3,275.54
2,730.00
2,303.99
1,963.83
1,574.54
Gross Profit
11,653.93
11,677.23
10,300.80
8,998.54
8,182.35
7,020.63
4,824.25
3,125.32
2,323.41
2,417.65
2,000.90
GP Margin
56.14%
59.69%
62.57%
60.35%
59.32%
57.92%
59.56%
53.38%
50.21%
55.18%
55.96%
Total Expenditure
16,481.35
15,611.61
12,691.28
11,475.26
10,606.53
9,556.90
5,966.14
4,994.37
4,066.10
3,418.22
2,752.25
Power & Fuel Cost
-
556.79
470.95
437.14
419.26
359.60
349.84
324.72
232.36
208.26
194.91
% Of Sales
-
2.85%
2.86%
2.93%
3.04%
2.97%
4.32%
5.55%
5.02%
4.75%
5.45%
Employee Cost
-
2,584.87
2,130.84
1,767.76
1,542.62
1,302.26
802.43
663.31
535.69
425.07
324.13
% Of Sales
-
13.21%
12.94%
11.86%
11.18%
10.74%
9.91%
11.33%
11.58%
9.70%
9.07%
Manufacturing Exp.
-
2,037.95
1,534.44
1,309.64
1,256.18
1,022.70
772.04
623.04
543.16
511.60
349.01
% Of Sales
-
10.42%
9.32%
8.78%
9.11%
8.44%
9.53%
10.64%
11.74%
11.68%
9.76%
General & Admin Exp.
-
1,006.68
1,068.21
997.32
686.38
666.38
283.49
197.83
130.74
120.34
116.94
% Of Sales
-
5.15%
6.49%
6.69%
4.98%
5.50%
3.50%
3.38%
2.83%
2.75%
3.27%
Selling & Distn. Exp.
-
1,122.67
1,025.85
848.43
901.87
878.98
359.60
305.98
208.20
141.59
143.56
% Of Sales
-
5.74%
6.23%
5.69%
6.54%
7.25%
4.44%
5.23%
4.50%
3.23%
4.02%
Miscellaneous Exp.
-
416.33
298.76
203.97
187.92
227.09
123.20
149.49
111.96
47.53
143.56
% Of Sales
-
2.13%
1.81%
1.37%
1.36%
1.87%
1.52%
2.55%
2.42%
1.08%
1.37%
EBITDA
4,276.52
3,951.94
3,771.75
3,434.28
3,188.12
2,563.62
2,133.65
860.95
561.30
963.26
823.19
EBITDA Margin
20.60%
20.20%
22.91%
23.03%
23.11%
21.15%
26.34%
14.70%
12.13%
21.98%
23.02%
Other Income
138.16
155.32
101.98
115.89
203.80
96.71
21.56
28.54
24.70
71.41
151.49
Interest
183.01
262.60
77.72
66.72
256.70
159.87
310.16
266.64
277.24
64.65
73.09
Depreciation
754.28
667.95
557.97
427.63
392.37
332.61
312.53
248.74
200.53
171.50
149.34
PBT
3,376.63
3,176.71
3,238.04
3,055.82
2,742.85
2,167.85
1,532.52
374.11
108.23
798.52
752.25
Tax
839.08
726.85
818.27
759.65
720.71
596.59
363.45
82.71
-88.81
225.12
191.36
Tax Rate
24.85%
23.53%
25.27%
24.86%
26.28%
27.52%
23.72%
22.11%
41.70%
28.56%
25.44%
PAT
2,537.55
2,362.03
2,420.03
2,296.64
2,023.64
1,575.77
1,172.85
293.86
-123.50
563.45
561.21
PAT before Minority Interest
2,537.86
2,361.80
2,419.77
2,296.17
2,022.14
1,571.26
1,169.07
291.40
-124.14
563.06
560.89
Minority Interest
0.31
0.23
0.26
0.47
1.50
4.51
3.78
2.46
0.64
0.39
0.32
PAT Margin
12.22%
12.07%
14.70%
15.40%
14.67%
13.00%
14.48%
5.02%
-2.67%
12.86%
15.70%
PAT Growth
7.62%
-2.40%
5.37%
13.49%
28.42%
34.35%
299.12%
-
-
0.40%
 
Unadjusted EPS
43.44
40.36
41.36
39.33
34.67
27.03
40.27
10.09
-4.24
19.57
20.81

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
13,890.78
11,680.42
9,371.91
7,287.30
5,155.91
3,750.15
2,605.76
2,339.65
2,444.83
1,829.08
Share Capital
58.59
58.59
58.59
58.52
29.20
29.15
29.12
29.11
29.11
27.86
Total Reserves
13,832.13
11,621.76
9,313.22
7,227.50
5,126.71
3,721.00
2,576.64
2,310.54
2,415.72
1,801.22
Non-Current Liabilities
335.81
583.54
102.07
583.85
1,591.60
1,493.91
1,225.26
967.29
645.49
2,245.74
Secured Loans
179.95
26.96
177.59
380.10
773.54
1,101.31
1,084.11
862.08
449.74
864.05
Unsecured Loans
0.00
424.24
3.81
362.71
587.93
178.05
64.15
102.55
73.61
1,290.51
Long Term Provisions
46.54
55.86
39.13
23.36
24.35
9.18
9.00
4.24
3.09
0.00
Current Liabilities
12,042.90
8,680.62
6,605.60
7,840.22
6,136.40
4,220.04
3,430.83
2,915.05
2,768.49
707.99
Trade Payables
2,677.13
2,627.44
2,154.70
2,457.03
2,051.13
1,351.20
963.75
660.14
776.35
604.40
Other Current Liabilities
2,545.41
1,777.80
1,286.82
1,577.58
1,364.95
387.68
150.87
580.34
699.09
68.40
Short Term Borrowings
6,573.21
4,031.34
2,902.72
3,672.68
2,502.08
2,354.56
2,236.12
1,608.21
1,234.73
0.00
Short Term Provisions
247.15
244.04
261.36
132.93
218.24
126.60
80.09
66.36
58.32
35.19
Total Liabilities
26,271.08
20,946.40
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85
6,232.20
5,867.93
4,787.14
Net Block
8,474.85
6,520.68
4,833.78
4,179.69
3,705.64
2,721.67
2,638.87
2,194.65
1,738.60
1,710.85
Gross Block
10,497.62
7,894.78
5,635.49
4,569.83
5,446.13
4,182.96
3,763.47
3,086.25
2,438.00
2,407.67
Accumulated Depreciation
2,022.77
1,374.10
801.71
390.14
1,740.49
1,461.29
1,124.60
891.60
699.40
696.82
Non Current Assets
10,906.57
8,758.56
6,875.48
5,419.57
4,610.93
3,858.59
3,136.10
2,968.16
2,546.75
2,280.47
Capital Work in Progress
1,668.46
1,583.04
1,458.08
848.14
370.35
256.67
167.82
515.74
582.86
570.08
Non Current Investment
360.20
311.52
245.85
122.94
0.14
19.76
22.24
19.86
38.49
-0.46
Long Term Loans & Adv.
364.44
255.76
256.48
236.56
455.27
789.04
237.82
108.12
110.77
0.00
Other Non Current Assets
38.62
87.56
81.29
32.24
30.25
18.40
18.66
0.12
1.47
0.00
Current Assets
15,364.51
12,187.84
9,206.18
10,294.35
8,298.80
5,631.18
4,136.75
3,264.04
3,321.18
2,506.67
Current Investments
0.02
0.02
0.02
0.02
19.65
0.03
0.04
18.68
0.04
0.74
Inventories
7,245.60
5,858.41
4,330.54
4,056.14
3,611.30
2,367.54
1,923.59
1,545.56
1,455.27
1,102.45
Sundry Debtors
3,413.78
3,084.36
2,765.33
4,606.68
3,539.17
2,636.57
1,596.98
1,239.96
1,230.98
956.01
Cash & Bank
1,957.18
1,261.62
513.48
800.26
469.11
178.58
208.45
70.86
186.72
72.83
Other Current Assets
2,747.93
1,223.32
1,084.72
464.37
659.57
448.46
407.69
388.98
448.17
374.64
Short Term Loans & Adv.
828.11
760.11
512.09
366.88
387.90
237.22
207.51
216.67
358.87
280.60
Net Current Assets
3,321.61
3,507.22
2,600.58
2,454.13
2,162.40
1,411.14
705.92
348.99
552.69
1,798.68
Total Assets
26,271.08
20,946.40
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85
6,232.20
5,867.93
4,787.14

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
1,622.03
1,954.82
3,278.58
1,419.76
1,236.81
646.28
274.87
326.25
335.11
425.18
PBT
3,091.35
3,241.18
3,060.84
2,744.30
2,167.85
1,532.52
374.11
108.23
798.52
752.25
Adjustment
810.77
535.02
408.92
487.50
406.28
515.12
441.54
387.22
197.72
99.77
Changes in Working Capital
-1,510.26
-1,068.98
582.52
-1,079.41
-841.73
-1,057.41
-421.56
-128.34
-469.45
-273.72
Cash after chg. in Working capital
2,391.86
2,707.22
4,052.28
2,152.39
1,732.40
990.23
394.09
367.11
526.79
578.30
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-769.83
-752.40
-773.70
-732.63
-495.59
-343.95
-119.22
-40.86
-191.68
-153.12
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-2,876.83
-1,956.95
-1,787.04
-1,445.21
-1,397.97
-818.74
-246.34
-563.16
-599.07
-399.02
Net Fixed Assets
-799.00
-771.00
-1,092.24
125.11
-533.87
-141.02
-224.46
-376.05
-396.28
-478.66
Net Investments
-371.56
-285.55
-498.60
-170.60
-140.13
-164.64
-78.98
-135.92
-122.17
-101.50
Others
-1,706.27
-900.40
-196.20
-1,399.72
-723.97
-513.08
57.10
-51.19
-80.62
181.14
Cash from Financing Activity
1,919.06
864.15
-1,915.26
365.44
93.21
117.64
108.09
118.85
406.98
-84.04
Net Cash Inflow / Outflow
664.26
862.02
-423.72
339.99
-67.95
-54.82
136.62
-118.06
143.02
-57.88
Opening Cash & Equivalents
1,209.94
319.63
743.49
403.81
148.02
202.73
65.64
183.71
44.72
102.65
Closing Cash & Equivalent
1,875.58
1,211.84
319.63
743.50
461.10
148.02
202.73
65.64
183.71
47.19

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
237.08
199.36
159.96
124.50
88.29
64.33
44.74
40.19
41.99
32.83
ROA
10.00%
13.07%
14.44%
14.13%
14.03%
13.95%
4.32%
-2.05%
10.57%
12.45%
ROE
18.47%
22.99%
27.57%
32.51%
35.29%
36.79%
11.78%
-5.19%
26.35%
36.54%
ROCE
17.97%
22.72%
24.92%
27.35%
27.18%
27.18%
11.17%
1.25%
19.29%
21.84%
Fixed Asset Turnover
2.13
2.44
2.96
2.79
2.55
2.08
1.75
1.71
1.85
1.67
Receivable days
60.58
64.70
89.16
106.53
91.84
93.55
86.28
95.44
89.07
92.25
Inventory Days
122.24
112.70
101.43
100.27
88.91
94.82
105.51
115.91
104.17
98.97
Payable days
60.06
71.58
75.73
81.50
67.49
71.06
57.79
64.70
70.79
72.18
Cash Conversion Cycle
122.76
105.81
114.86
125.30
113.25
117.31
134.00
146.65
122.45
119.04
Total Debt/Equity
0.50
0.41
0.36
0.69
0.86
1.01
1.32
1.32
0.99
1.18
Interest Cover
12.76
42.66
46.80
11.69
14.56
5.94
2.40
0.23
13.19
11.29

Annual Reports:

FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012
FY 2011
FY 2010

News Update:


  • Aurobindo Pharma’s arm signs deal to set up JV in China
    31st Aug 2019, 15:33 PM

    Helix Healthcare S.V, Netherlands, has entered into an agreement with Shanghai LongJin Investment Company, China and Sveva Capitals, Hongkong

    Read More
  • Aurobindo Pharma reports 40% rise in Q1 consolidated net profit
    8th Aug 2019, 09:59 AM

    Total consolidated income of the company increased by 27.16% at Rs 5,460.38 crore for Q1FY20

    Read More
  • Aurobindo Pharma - Quarterly Results
    7th Aug 2019, 18:47 PM

    Read More
  • Aurobindo Pharma launches Cinacalcet Hydrochloride Tablets
    11th Jul 2019, 09:01 AM

    Cinacalcet Hydrochloride tablets had an annual sale of approximately $1,449 million for the twelve months ending May 2019

    Read More
  • USFDA pulls up Aurobindo Pharma for 'repeated' failures in CGMP
    4th Jul 2019, 11:47 AM

    The repeated failures at multiple sites demonstrate that management oversight and control over the manufacture of drugs are inadequate

    Read More
  • Aurobindo Pharma receives warning letter from USFDA for API manufacturing facility
    21st Jun 2019, 10:43 AM

    This action follows the earlier inspection of the site by the USFDA in February 2019

    Read More
  • Aurobindo Pharma to invest $200 million on Capex in FY20
    17th Jun 2019, 10:01 AM

    The majority of the CAPEX should be in terms of creating certain both finished dosage and API capacities

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.